Stocktoria
Chugai Pharmaceutical Co., Ltd. 4519.T
JP · Tokyo Stock Exchange · XTKS · stock · Healthcare · website
Chugai Pharmaceutical Co., Ltd. financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $1.26T | $1.17T | $1.11T | $1.26T |
| Gross profit | $894.3B | $831.2B | $698.1B | $783.5B |
| R&D expense | $187.6B | $181.4B | $174.9B | $149.6B |
| SG&A expense | $116.5B | $110.1B | $112.6B | $100.5B |
| Operating income | $598.8B | $542.0B | $439.2B | $533.3B |
| Interest expense | $207.0M | — | $27.0M | $61.0M |
| Income tax | $163.8B | $155.7B | $118.3B | $156.7B |
| Operating cash flow | $386.3B | $447.6B | $409.9B | $243.6B |
| Free cash flow | $274.7B | $392.7B | $335.7B | $172.3B |
| Cash & equivalents | $426.6B | $540.2B | $458.7B | $222.2B |
| Inventory | $276.8B | $240.1B | $273.5B | $292.2B |
| Total assets | $2.47T | $2.21T | $1.93T | $1.87T |
| Total liabilities | $442.9B | $306.9B | $307.0B | $445.4B |
| Shareholders' equity | $2.03T | $1.90T | $1.63T | $1.42T |
| EPS (diluted) | $263.72 | $235.36 | $197.80 | $227.57 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +7.5% | +5.3% | -11.8% | — |
| EPS growth | +12.0% | +19.0% | -13.1% | — |
| Free cash flow growth | -30.1% | +17.0% | +94.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · JP · as of 2025-12-31. Figures in JPY; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.